A lack of association between adiponectin polymorphisms and coronary artery disease in a Chinese population by Zhong, Chen et al.
A lack of association between adiponectin polymorphisms and coronary
artery disease in a Chinese population
Chen Zhong, Ding Zhen, Qian Qi and Ma Genshan
Department of Cardiology, The Affiliated ZhongDa Hospital and Institute of Cardiovascular Disease,
Southeast University, Nanjing, P.R. China.
Abstract
We investigated the association between two single nucleotide polymorphisms (SNPs) in the adiponectin gene
(rs822395 and rs266729) and coronary artery disease (CAD) in a case-control study of 198 unrelated Chinese CAD
patients (with  70% coronary stenosis or previous myocardial infarction) and 237 non-CAD controls. The ligase re-
action was used to detect SNPs rs822395 and rs266729, and the allelic association of these SNPs with the occur-
renceandseverityofCADwasassessed.Therewerenosignificantdifferencesinthegenotypicorallelicfrequencies
of the two SNPs between control and CAD individuals. In addition, there was no association between the two SNPs
and the severity of CAD based on the number of diseased vessels. The frequencies of alleles C and G at rs266729
differed significantly between females in the CAD and control groups, but not between males. Female carriers of al-
lele G at rs266729 had a higher risk of CAD compared with allele C carriers (OR = 1.30, 95% CI: 1.09-2.64, p = 0.02).
These results indicate a gender-specific effect of the adiponectin gene rs266729 variant in modulating the risk of
CAD in women.
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Introduction
Coronary artery disease (CAD) is one of the most
common cardiovascular diseases and has a high incidence
of morbidity and mortality. CAD is a major public health
problem in developing and developed countries and its in-
creasing prevalence is a cause of considerable concern in
the medical community worldwide (He et al., 2005). CAD
involves genetic and environmental factors and their inter-
action with each other. Traditional risk factors account for
at most one-half of the prevalence of CAD (Wilson et al.,
1998; Zdravkovic et al., 2002). Despite attempts to estab-
lish the molecular and genetic determinants that could ac-
count for variations in CAD (Zdravkovic et al., 2002), the
etiology and complex multigenic basis of atherosclerosis is
still not completely understood.
Adiponectin is an adipocyte-derived protein, the plasma
levelsofwhichhavebeenusedasamarkerofinflammation
and hemostasis. Adiponectin has received considerable at-
tentioninrecentyearsbecauseofitsinsulin-sensitizingand
anti-atherogenic activity; indeed, several studies have indi-
catedagradualdecreaseinthecirculatinglevelsofthispro-
teinwithincreasinginsulinresistance(Haluzíketal.,2004;
Fisher et al., 2005; Kadowaki and Yamauchi, 2005; Ka-
wano and Arora, 2009). Adiponectin gene activity has an
important influence on the susceptibility to insulin resis-
tance, a core determinant of prevalent disorders such as
type 2 diabetes mellitus (T2DM), metabolic syndrome and
atherosclerosis (Hara et al., 2002; Menzaghi et al., 2002,
2007;Rothenbacheretal.,2005).Variousstudieshavesug-
gested that genetic deficits in adiponectin production or ac-
tion may contribute to insulin resistance (Filippi et al.,
2004),atherosclerosis(Kubotaetal.,2002),andinflamma-
tion (Ouchi et al., 1999; Kubota et al., 2002; Tilg and
Moschen, 2008), all of which are frequently associated
with CAD.
In laboratory animals, recombinant adiponectin im-
proves insulin sensitivity, inhibits inflammatory responses
and reverses diet-induced lipid abnormalities (Kadowaki
and Yamauchi, 2005). Furthermore, when apo E-deficient
mice (a model of accelerated atherosclerosis) are crossed
withadiponectintransgenicmicetheprogressionofathero-
sclerosis is inhibited, despite unaltered glucose and lipid
metabolism, which suggests that adiponectin has a direct
antiatherogenic action (Yamauchi et al., 2003; von Eynat-
ten et al., 2006).
In humans, low levels of adiponectin are associated
with an increased risk of cardiovascular disease that in-
cludes a characteristic profile of metabolic syndrome, such
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Research Articleas a low level of high-density lipoprotein cholesterol
(HDL-C), high triglyceride (TG) levels and insulin resis-
tance (Matsubara et al., 2002; Cnop et al., 2003; Ryo et al.,
2004; Trujillo and Scherer, 2005). However, both positive
(Kumada et al., 2003; Rothenbacher et al., 2005; Otsuka et
al., 2006, 2007; Selcuk et al., 2008) and negative (Sattar et
al., 2006; Kuller et al., 2007; Gui et al., 2008; Rizza et al.,
2009; Karakas et al., 2010) correlations between adipo-
nectin levels and CAD have been reported. In particular,
the relationship between common adiponectin variants
(rs266729,-11365C>G;rs822395,-4034A>C;rs822396,
-3964A > G; rs2241766, +45T > G; and rs1501299,
+276G > T) and CAD is inconsistent and unconvincing
(Filippi et al., 2005; Pischon et al., 2007).
Although the identification of genetic variants of adi-
ponectin and their relationship with CAD are interesting
and promising, the controversial and often inconclusive
findings of most studies suggest that the data may be more
relevant if obtained from specific ancestral groups. In this
regard, there is little information on the relationship be-
tween two common SNPs in the adiponectin gene
(rs266729, -11365C > G; rs822395, -4034A > C) and the
risk of CAD in Chinese populations. In the present study,
we examined the relationship between these two SNPs and
the risk of CAD in Chinese patients and assessed whether
the presence of these SNPs correlated with the severity of
coronary lesions.
Methods
Subjects and study groups
From January 2003 to December 2008, 435 unrelated
subjects (men 31-86 years old and women 39-83 years old)
who were scheduled for elective coronary angiography
(CAG) for chest discomfort or suspected CAD were en-
rolled in the study. The CAD group consisted of 198 pa-
tients with documented CAD who had  70% stenosis in at
least one main coronary artery or had experienced a myo-
cardial infarction defined according to World Health Orga-
nization criteria. The control group consisted of 237
subjects with no detectable coronary stenosis in CAG. All
patients with congenital heart disease, syndrome X, severe
liverorkidneydisease,non-coronaryarterythromboticdis-
ease, or a contraindication for heparin were excluded from
the study. Written informed consent was obtained from all
participants before enrolling. The study protocol was ap-
proved by the Medical Ethics Committee of the Affiliated
ZhongDa Hospital of Southeast University.
Coronary angiography
All participants underwent elective CAG by the
Judkins technique, with images recorded on compact disks
for later analysis. The CAD cases were grouped according
to the number of significantly stenosed vessels, i.e., indi-
viduals with one, two or three affected vessels. Two cardi-
ologists unaware of the impact of their consensus opinion
on this study assessed the grade of coronary stenosis. All
participants were from the same geographical area and had
a similar socioeconomic and ethnic background. Patients
without coronary stenosis served as controls.
Determination of biochemical and clinical risk factors
At the time of enrollment, data were collected from
each subject, including a complete history of cardiovascu-
lar risk factors such as hypertension, T2DM and smoking
habit. Anthropometric and blood pressure measurements
were made according to standard protocols. Hypertension
wasdefinedasbloodpressure140/90mmHgortheuseof
antihypertensive medications. Subjects with a history of
T2DM, those receiving anti-diabetic medications, and
those with a confirmed fasting blood sugar (FBS) concen-
tration > 126 mg/dL (7.0 mmol/L) were considered to have
T2DM. Subjects who smoked at least one cigarette per day
at the time of enrollment were considered as smokers, as
were those who had smoked in the month before the study.
The body mass index (BMI) was calculated as weight in ki-
lograms divided by the square of the height in meters
(kg/m
2).
Venous blood samples for lipoprotein and FBS mea-
surements were collected into tubes containing 0.1%
EDTA after a 12 h fast. Plasma concentrations of total
cholesterol (TC), TG, HDL-C, low-density lipoprotein
cholesterol (LDL-C), apolipoprotein A1 (apo A1) and apo-
lipoprotein B (apo B) were determined by standard bio-
chemical methods using a chemical analyzer (Beckman
Coulter Synchron Clinical System LX20, Fullerton, CA,
USA). Plasma insulin concentrations were measured by a
commercial radioimmunoassay kit (Beifang Biotechnical
Institute, Beijing, China) with an inter-assay coefficient of
variation (CV) of 15% and intra-assay CV of 10%. TG was
measureddirectlywhen>4.52mmol/L(400mg/dL).Allof
the plasma samples were thawed only once.
DNA extraction and adiponectin genotyping
Genomic DNA was extracted from blood leucocytes
by using a whole-blood genomic DNA extraction kit (Axy-
gene Biotechnology Ltd., Hangzhou, China), according to
the manufacturer’s instructions. The two SNPs in rs822395
and rs266729 were genotyped by the ligase detection reac-
tion (Favis et al., 2000; Xiao et al., 2006) with TaqMan
genotyping assays in an ABI Prism 377 sequence detection
system (Applied Biosystems, Foster City, CA). Random
duplicate samples and sequencing technique were used for
quality control in the genotyping. The overall success rate
for genotyping was > 96%.
Statistical analysis
Continuous data were expressed as the mean  SD
and Students t-test was used to analyze differences
between the two study groups. Categorical variables
Zhong et al. 429between the two groups were compared by the chi-square
test and the genotype groups were compared with one-
way ANOVA or the chi-square test. The latter test was
alsousedtocomparetheallelicandgenotypicfrequencies
in the CAD and control groups with values predicted by
Hardy-Weinberg equilibrium, and to compare the distri-
bution of genotypes in the two SNPs with the severity of
coronary lesions. The odds ratios (with the 95% confi-
dence intervals) were calculated by logistic regression
analysis. Two-tailed p-values < 0.05 indicated signifi-
cance. All statistical analyses were done with SPSS ver-
sion 15.0 software (SPSS, Inc, Chicago).
Results
Baseline characteristics of the control and CAD
groups
Patients with CAD had a greater average age and
higher concentrations of insulin, TG and apo B when com-
pared with the controls (p < 0.05-0.01) (Table 1). The prev-
alence of hypertension and T2DM was significantly higher
in CAD patients than in the controls (p < 0.05). In contrast,
thetwogroupsdidnotdiffersignificantlyintheirmeanval-
ues for BMI, FBS, TC, LDL-C, HDL-C and apo A1, or in
their sex ratio, proportion of smokers, and family history of
cardiovascular diseases (CVD).
Polymorphism frequency and relationship to gender
Three genotypes were detected in rs822395 (AA, AC
andCC)andrs266729(CC,CGandGG).Therewasnode-
viation from Hardy-Weinberg equilibrium in the control
group,norweretheresignificantdifferencesinthefrequen-
cies of genotypes or alleles for these two SNPs between the
control and CAD groups (Table 2).
Table 3 shows the frequency of polymorphisms ac-
cording to gender. There were no significant differences in
the distribution of genotypes AA, AC and CC at rs822395
between women of the two groups (p = 0.27). In contrast,
the frequencies of alleles C and G at rs266729 showed bor-
derline significance (p = 0.07) between the control and
CADgroupsandfemalecarriersofalleleGatrs266729had
ahigherriskofCADthanalleleCcarriers(OR=1.30,95%
CI: 1.09-2.64, p = 0.02). There were no significant differ-
ences in the distribution of these two SNPs among males of
the control and CAD groups (data not shown).
Distribution of genotypes for the two SNPs in
relation to the severity of coronary lesions
There were no significant differences in the frequen-
cies of polymorphisms for the two SNPs among CAD pa-
tients with one, two or three stenosed vessels (p = 0.77 and
p = 0.53 for rs822395 and rs266729, respectively) (data not
430 Adiponectin polymorphism and coronary artery disease
Table 1 - Baseline characteristics of the two groups studied.
Control CAD
Number of individuals 237 198
Gender – male (%) 109 (46.0) 107 (54.0)
Age (years) 54.5  10.2 60.6  10.1
†
Hypertension (%) 129 (54.4) 130 (65.7)
*
Type 2 diabetes mellitus (%) 29 (12.2) 42 (21.2)
*
Smokers (%) 58 (24.5) 63 (31.8)
Family history of CVD (%) 76 (32.1) 75 (37.9)
BMI (kg/m
2) 24.40  4.35 24.96  4.35
Fasting blood glucose (mmol/L) 5.55  1.34 5.78  1.60
Insulin (mU/L) 12.83  10.17 15.51  10.80
*
TC (mmol/L) 4.47  0.92 4.67  0.91
TG (mmol/L) 1.51  0.94 1.80  0.93
†
LDL-C (mmol/L) 2.74  0.74 2.82  0.76
HDL-C (mmol/L) 1.16  0.26 1.16  0.28
Apo A1 (g/L) 1.17  0.23 1.15  0.21
Apo B (g/L) 0.84  0.27 0.92  0.28
*
Data are expressed as the number of individuals (percentage in parenthe-
ses) or the mean  SD, as appropriate.
*p < 0.05 and
†p < 0.01 vs. control
group. apo A1, apolipoprotein A1; apo B, apolipoprotein B; BMI, body
mass index; CAD, coronary artery disease; CVD, cardiovascular disease;
HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipo-
protein-cholesterol; TC, total cholesterol; TG, triglyceride.
Table 2 - Genotype and allele distributions for rs822395 and rs266729 in
control and CAD groups.
Control (%) CAD (%) OR (95% CI)
rs822395
AA 175 (73.8)* 143 (72.2)*
AC 59 (24.9) 48 (24.2) 1.00 (0.64-1.55)
CC 3 (1.3) 7 (3.5) 2.86 (0.73-11.24)
p 0.29
Relative allele frequencies
Allele A 409 (86.3) 334 (84.3)
Allele C 65 (13.7) 62 (157) 1.17 (0.80-1.7)
p 0.44
rs266729
CC 146 (61.6) 110 (55.6)
CG 76 (32.1) 72 (36.4) 1.26 (0.84-1.89)
GG 15 (6.3) 16 (8.1) 1.42 (0.67-2.99)
p 0.42
Relative allele frequencies
Allele C 368 (77.6) 292 (73.7)
Allele G 106 (22.4) 104 (26.3) 1.24 (0.91-1.69)
p 0.20
*Number of individuals with percentage in parentheses. CAD – coronary
artery disease, OR – odds ratio, 95% CI - 95% confidence interval. The
chi-squaretestandlikelihoodratiotestwereusedtoanalyzethegenotypes
and alleles, respectively. p is the level of significance for the CAD group
compared to the control group.shown). These findings indicate that there was no relation-
shipbetweengenotypeandtheseverityofcoronarylesions.
Discussion
The results of this investigation failed to demonstrate
anassociationbetweenSNPsrs822395andrs266729ofthe
adiponectin gene and CAD in a Chinese population, al-
though the frequencies of alleles C and G at rs266729 in fe-
males showed borderline significance between the control
and CAD groups, and female carriers of allele G at
rs266729 had a higher risk of CAD compared with allele C
carriers.
Adiponectin is a 244-amino acid protein that is se-
creted exclusively by adipocytes. This protein has been
proposed to protect against CVD via its metabolic anti-
inflammatory effects mediated by cross-talk between the
cAMP-PKA and NF-kappaB signaling pathways (Ouchi et
al., 2000), by down-regulating adhesion molecule expres-
sion on endothelial cells (Ouchi et al., 1999), and by acting
inthehomeostaticcontrolofglucose,lipid,andenergyme-
tabolism with consequent lipid clearance and reversal of
cardiovascular risk factors (Matsubara et al., 2002; Cnop et
al., 2003; Ryo et al., 2004; Trujillo and Scherer, 2005;
Kawano and Arora, 2009). Adiponectin also stimulates
fatty acid oxidation, decreases plasma TG and improves
glucose metabolism by increasing insulin sensitivity (Ha-
luzík et al., 2004; Kawano and Arora, 2009). However, the
lack of consistent data on the association between adipo-
nectin, its genetic variants and the risk of CAD means that
the precise role of this protein in CAD and CVD in general
is still unclear (Antoniades et al., 2009).
Although the adiponectin gene has been considered a
candidate gene for CAD, Pischon et al (2007) recently
showed that of five common SNPs for this gene (rs266729,
-11365C > G; rs822395, -4034A > C; rs822396,
-3964A > G; rs2241766, +45T > G; and rs1501299,
+276G > T) only the -4034CC genotype was related to an
increased risk of nonfatal myocardial infarction or fatal
CAD compared with the AA genotype in women [relative
risk (RR): men, 1.69; 95% CI: 0.99-2.89; women, 2.04;
95% CI: 1.20-3.49]; other SNPs or haplotypes defined by
thefiveSNPswerenotconsistentlyrelatedtoariskofCAD
or to the plasma levels of adiponectin.
In the patients from eastern China studied here, there
was no significant association between the SNPs rs822395
and rs266729 and the risk of CAD. However, female CAD
patientshadahigherfrequencyofalleleGatrs266729than
control females, and female carriers of allele G at rs266729
had a greater risk of CAD compared with allele C carriers.
These findings suggest that genetic factors may exert a
greater influence in CAD in women than in men. Indeed,
epidemiological data show that the risk of CAD differs be-
tween female and male patients as a result of hormonal dif-
ferences and variable exposure to the risk factors involved
in disease progression. This is the first report of a gen-
der-specific relationship between the rs266729 variant of
the adiponectin gene and the risk of CAD, and differs from
the results reported by Pischon et al. (2007). The reasons
for this discrepancy are unclear, although ethnic and geo-
graphic differences in the populations studied could partly
accountforthesevariations.TheCADpatientsstudiedhere
hadagreaterprevalenceofhypertensionandT2DM,higher
levelsofinsulin,TGandapoB,andagreatermeanagethan
the controls.
This study has some limitations that could influence
the interpretation of our results. First, the study cohort was
obtained from a single hospital in eastern China so it is un-
likely that the subjects adequately represented the charac-
teristics of populations included in other studies. However,
the well-designed study protocol and methods used here,
together with the fact that all of the participants enrolled in
the CAD and non-CAD groups underwent elective CAG
meant that our results were reliable for the population stud-
ied. Second, since we did not measure the circulating adi-
ponectinlevelsitwasnotpossibletoassesstheeffectofge-
netic variants of adiponectin on protein production – the
limiteddataavailableintheliteratureindicatenoconsistent
relationship between adiponectin variants and the plasma
concentrations of this protein. Third, since CAD is pro-
ducedbyavarietyofgenesandenvironmentalfactors,vari-
ous other genes could potentially contribute to the overall
phenotypeofCAD.Thissituationisfurthercomplicatedby
the fact that some risk factors for CAD, e.g., certain geno-
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Table 3 - Genotype and allele distributions for rs822395 and rs266729
among women in the control and CAD groups.
Control (%) CAD (%) OR (95% CI)
rs822395
AA 97 (75.8) 72 (79.1)
AC 29 (22.0) 15 (16.5) 0.70 (0.35-1.40)
CC 2 (1.6) 4 (4.4) 2.69 (0.48-15.12)
p 0.27
Relative allele frequencies
Allele A 223 (87.1) 159 (87.4)
Allele C 33 (12.9) 23 (12.6) 0.98 (0.55-1.73)
p 0.94
rs266729
CC 84 (65.6) 46 (50.5)
CG 37 (28.9) 36 (39.6) 1.78 (0.99-3.18)
GG 7 (5.5) 9 (9.9) 2.35 (0.82-6.72)
p 0.07
Relative allele frequencies
Allele C 205 (80.1) 128 (70.3)
Allele G 51 (19.9) 54 (29.7) 1.30 (1.09-2.64)
p 0.02
See Table 2 for abbreviations.types and alleles, may be specific for particular ethnic
and/or geographic populations. We therefore cannot ex-
clude the possibility that gene-gene and/or gene-environ-
ment interactions may have influenced the results obtained
here.
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